

04 October 2022

Intra-vitreous injections or implants

Request

I am analysing the usage of **intra-vitreous injections or implants** by the NHS. I would greatly appreciate if you could answer the following questions:

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2022:

- Aflibercept **3674**
- Bevacizumab **3**
- Brolucizumab **0**
- Dexamethasone **39**
- Faricimab **0**
- Ranibizumab – Lucentis **1449**
- Ranibizumab – Ongavia **0**

2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2022.

Number of Injections/Implants: May - August 2022

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	2791	386	497
Bevacizumab	2	1	0
Brolucizumab	0	0	0
Dexamethasone	29	2	8
Faricimab	0	0	0
Ranibizumab - Lucentis	973	356	120
Ranibizumab - Ongavia	0	0	0